NFA
FATE icon

Nationwide Fund Advisors’s Fate Therapeutics FATE Stock Holding History

Nationwide Fund Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-21,117
Closed -$84K – 699
2017
Q3 		$84K Hold
21,117
– – ﹤0.01% 2959
2017
Q2 		$68K Buy
+21,117
New +$80.9K ﹤0.01% 3018
2016
Q3 		– Sell
-22,578
Closed -$38K – 3232
2016
Q2 		$38K Hold
22,578
– – ﹤0.01% 3109
2016
Q1 		$41K Buy
+22,578
New +$46.5K ﹤0.01% 3021

Other funds holding FATE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nationwide Fund Advisors's FATE Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Fate Therapeutics (FATE) in Q4 2017, closing a stake of 21,117 shares — an estimated $84K sold.

Nationwide Fund Advisors first reported a position in FATE in Q1 2016 and held it in 4 quarters. The position peaked at $84K in Q3 2017. 78 funds tracked by Wall St. Rank hold FATE as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Fate Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 21,117 Fate Therapeutics shares in Q4 2017, an estimated $84K.
  • Nationwide Fund Advisors first reported a position in Fate Therapeutics in Q1 2016 and held it in 4 quarters.
  • Nationwide Fund Advisors's Fate Therapeutics position peaked at $84K in Q3 2017.
  • 78 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.